Reduced Effect from Clopidogrel [Plavix] in “Poor Metabolizer” Patients
Last Updated on November 6, 2015 by Joseph Gut – thasso
Through a new boxed warning, the FDA is alerting healthcare professionals about a subgroup of patients who cannot effectively metabolize the anti-platelet drug Clopidogrel [Plavix].
These patients, called “poor metabolizers,” have little or no activity of the liver enzyme CYP2C19, which converts Clopidogrel [Plavix] to its active form, so they may not experience the full anti-clotting benefits of the drug.
Practitioners should know that tests are available to identify genetic differences in CYP2C19 function and thus identify poor metabolizers. They should consider using other anti-platelet medication or an alternative dosing strategy for these patients. And although raising the dose of Clopidogrel [Plavix] in poor metabolizers can increase anti-platelet response, an appropriate dose regimen has not been established in a clinical trial.
Please find additional information here:
FDA MedWatch Safety Alert. Plavix (clopidogrel): Reduced effectiveness in patients who are poor metabolizers of the drug. March 12, 2010.
...August 3, 2017
Februa...February 2, 2022
Ma...March 25, 2017
29 Jul...July 29, 2022
June 0...June 3, 2016